AGÕæÈ˹ٷ½

STOCK TITAN

[SCHEDULE 13G] Teva Pharmaceutical Industries Limited American SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: With regard to rows (6), (8), (9) and (11), the beneficial ownership of the securities reported herein is described in Item 4(a). With regard to rows (6), (8), and (9), the amount of shares includes 38,000,044 Ordinary Shares held in 38,000,044 of the issuer's American depositary shares ("ADSs"). Each ADS represents one Ordinary Share Row (11) is Based on 1,146,838,689 Ordinary Shares outstanding as of July 15, 2025 (as reported on Bloomberg LP).


SCHEDULE 13G



Phoenix Financial Ltd.
Signature:/s/ Eli Schwartz
Name/Title:Vice President - Chief Financial
Date:07/21/2025
Signature:/s/ Haggai Schreiber
Name/Title:Executive Vice President - Chief Investment Officer
Date:07/21/2025

Comments accompanying signature: Signature duly authorized by resolution of the Board of Directors, notice of which is attached as Exhibit 1 to this Schedule 13G.
Exhibit Information

Exhibit 1 - Notice of resolution of the Board of Directors of Phoenix Financial Ltd., dated as of December 12, 2019 (incorporated herein by reference to Exhibit 1 to the Schedule 13G filed on February 1, 2024).

Teva Pharm

NYSE:TEVA

TEVA Rankings

TEVA Latest News

TEVA Latest SEC Filings

TEVA Stock Data

21.08B
1.15B
0%
66.16%
4.35%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Israel
TEL AVIV